In this study, we compared monovalent and bivalent IAP antagonists in the context of cIAP1 auto-ubiquitylation/degradation in sensitive cancer cells and found fundamental differences between these classes of IAP antagonists. The gene discussed is BIRC2; the disease is cancer.